Top
Skip links

Clinical Trials
and Research Opportunities

Research is the key!

Research is the key to unlocking future treatments and potential cures for SCN2A-related disorders. The FamilieSCN2A Foundation is a global leader in sponsoring and funding critical research projects that aim to increase understanding of the disorders and work toward patient-centered drug development goals.

The FamilieSCN2A Foundation focuses on critical research projects such as patient registries, natural history studies, and clinical trial readiness research. This research is essential to the drug development process, and all people with SCN2A-related disorders are encouraged to participate.

In addition to Foundation-sponsored research, FamilieSCN2A works closely with partner organizations to highlight research opportunities of interest to the SCN2A community, including clinical trials for experimental treatments.

The community is encouraged to review the research opportunities and reach out to the research team with any questions.

FamilieSCN2A Foundation Research Projects

The Dragonfly Study

Observational / Global Patient Registry for SCN2A-Related Disorders
Currently Enrolling

The FamilieSCN2A Foundation, in partnership with the National Organization for Rare Disorders (NORD), has launched the DRAGONFLY Study, a Patient Registry with global reach to study SCN2A-related disorders (SRDs). As a Patient Registry, the DRAGONFLY Study creates a platform for patients around the world to strengthen their voices and provide critical information about their experiences living with SRDs. Its purpose is to build an international resource to be used by researchers and clinicians to advance drug development and treatment options to help improve SCN2A-Related Disorder patient care.

The Butterfly Study

Survey of Bereaved Caregivers of Individuals with SCN2A-Related Disorders
Enrolling soon

The insights gathered through this study will help us better understand the circumstances surrounding SCN2A-related deaths and guide future efforts to strengthen care, support and resources for families.

Clinical Picture Maker

Observational / Video Documentation and Sharing

Supplement to Patient Registry and Natural History Studies
Currently Enrolling

The Clinical Picture Maker is an online platform which aims to facilitate the creation, organization, and dissemination of video documentation of rare diseases. The CPM includes the DAYTool, a web application which guides individuals with rare disorders and their families to record and upload videos demonstrating all different aspects of life with their rare disorder.

SCN2A Clinical Trial Readiness Study

Observational
Study Completed

The CTRS was a prospective study that collected data over a one year period to identify the most effective tools to measure changes in SCN2A patients. This type of data is important when developing treatments in order to demonstrate a treatment's effectiveness.

The Inchstone Project

Observational / Clinical Outcome Measures Study
Study Completed

The Inchstone Project is a multidisciplinary collaborative effort to develop precise outcome measures for those who rarely achieve traditionally measurable “milestones.” The goal is to have FDA approved measures that have been adapted to work for those severely impacted DEEs.

Non-Interventional Research Studies

Below is a non-exhaustive list of observational and non-interventional research studies run by external organizations which may be of interest to the SCN2A community. Please reach out to the research team to help answer any questions.

Simons Searchlight​

Currently Enrolling​

Simons Searchlight focuses on rare genetic conditions by collecting quality data and connecting researchers, families, and advocates. This helps improve understanding of your genetic condition for the community, scientists, and doctors. It was the first SCN2A registry and also acts as a natural history study for ongoing participants.

Citizen Health

Currently Enrolling​

Citizen collects, organizes, and harmonizes clinical data from patient medical records to deliver a cost-effective natural history dataset without burdening patients with clinic visits.

Clinical Trials and Interventional Research Opportunities

Below is a non-exhaustive list of clinical trials and interventional research studies run by external organizations which may be of interest to the SCN2A community. The FamilieSCN2A Foundation is sharing for informational purposes only without explicit endorsement. Please reach out to the study sponsor for specific enrollment details. The FamilieSCN2A Foundation research team is also available to help answer any questions or guide families toward opportunities.

SCN2A Gain of Function (+)
Praxis Precision Medicines
Phase 1/2 - Currently Enrolling in Brazil only; Completed in United States
Study medication: Elsunersen (PRAX-222)
Antisense Oligonucleotide (ASO)
Genetic variants: SCN2A Gain of Function (GOF)
For children with early-onset SCN2A Developmental and Epileptic Encephalopathies (DEE).
Praxis Precision Medicines
Phase 3 - not yet enrolling
Study medication: Elsunersen (PRAX-222)
Antisense Oligonucleotide (ASO)
Genetic variants: SCN2A Gain of Function (GOF)
For children with early-onset SCN2A Developmental and Epileptic Encephalopathies (DEE).
SCN2A Loss of Function (-)
All known drug candidates for SCN2A Loss of Function (-) are in the preclinical stage of development, and are not currently recruiting for participants. Updates will be posted here.
SCN2A Mixed Function (+/-)
All known drug candidates for SCN2A Mixed Function (+/-) are in the preclinical stage of development, and are not currently recruiting for participants. Updates will be posted here.

Epilepsy Clinical Trials

Praxis Precision Medicines
Phase 2/3 - Currently Enrolling
Study medication: Relutrigine (PRAX-562)
Small Molecule
Genetic variants: SCN2A or SCN8A
For children with early-onset SCN2A or SCN8A Developmental and Epileptic Encephalopathies (DEE)
Praxis Precision Medicines
Phase 3 - Not Yet Enrolling
Study medication: Relutrigine (PRAX-562)
Small Molecule
Genetic variants: SCN2A or SCN8A
For individuals with Developmental and Epileptic Encephalopathies (DEE)
Longboard Pharmaceuticals
Phase 3 - Currently Enrolling
Study medication: Bexicaserin (LP352)
Small Molecule
Children and Adults with Developmental and Epileptic Encephalopathies (DEE).​
Praxis Precision Medicines
Phase 3 - Currently Enrolling
Study medication: Vormatrigene (PRAX-628)
Small Molecule
Adults with focal onset epilepsy
Neurona Therapeutics
Phase 1/2 - Currently Enrolling
Study medication: NRTX-1001
Neuronal Cell Therapy
Adults with drug-resistant bilateral mesial temporal lobe epilepsy
SK Life Science, Inc.
Phase 3 - Currently Enrolling
Study medication: Carisbamate
Small molecule
Children and adults (4 to 55 years of age) with Lennox-Gastaut syndrome (LGS)
Xenon Pharmaceuticals Inc.
Phase 3 - Currently Enrolling
Study medication: Azetukalner (XEN1101)
Small molecule
Adults with focal-onset seizures (FOS) or primary generalized tonic-clonic seizures (PGTCS),
Mid-Atlantic Epilepsy and Sleep Center, LLC
Currently Enrolling
Possible study medications include: SOTICLESTAT, CARISBAMATE, BEXICASERIN, LORCASERIN, CENOBAMATE, STACCATO, ALPRAZOLAM, GANAXOLONE, OPC-214870
Small molecules
Individuals with epilepsy

Autism Clinical Trials

Johns Hopkins University
Phase 1 - Currently enrolling
Study medication: Cannabidiol
Small molecule
Adults ages 18 or older with autism spectrum disorder (ASD) and who have a significant mood disorder or other behaviors that interfere with function and quality of life
MapLight Therapeutics
Phase 2 - Currently enrolling
Study drug: ML-004
Small molecule
Individuals ages 12 to 45 with autism spectrum disorder (ASD)
Intra-Cellular Therapies
Phase 3 - Currently enrolling
Study drug: Lumateperone
Small molecule
Pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD)

Personalized Medicine (N=1)

n-Lorem
Limited Eligibility
c.2558 G>A; p.Arg853Gln c.5645 G>A; p.Arg1882Gln
ASO
"We have a therapy available for a nano-rare patient with a mutation in the SCN2A gene that has the potential to help other patients with a mutation in this gene. If you are a patient or patient family or a physician of a potential patient, please email us at info@nlorem.org for more information on this program." Contact n-Lorem team for eligibility information

ClinicalTrials.gov is a database to learn about clinical studies from around the world